This site is intended for Healthcare Professionals only.

Valproate National Patient Safety Alert – GPhC tells what pharmacists need to do

Date:

Share post:

Pharmacy teams should be prepared to discuss the current warnings and upcoming measures with their patients

The General Pharmaceutical Council (GPhC) on Thursday sent an email to all pharmacy professionals to update them about a Valproate National Patient Safety Alert issued by the Medicines and Healthcare products Regulatory Agency (MHRA).

From January 2024, the MHRA is introducing the first phase of new regulatory measures to reduce the known harms of valproate, a drug used to treat epilepsy and bipolar disorder.

The health regulator has cautioned that the drug may cause serious harm to the baby, if taken during pregnancy, and lead to impaired fertility in males.

Integrated Care Boards in England and Health Boards in Scotland and Wales have been instructed to designate a new or existing group to prepare for and co-ordinate the implementation of the measures for oversight of prescribing valproate to new patients and existing female patients.

Meanwhile, the GPhC has informed pharmacy teams that they should be prepared to discuss the current warnings and upcoming measures with their patients.

However, pharmacist should continue to dispense valproate, as well as remind patients who are taking the drug that they must not stop taking their treatment without advice from their specialist.

Additionally, the regular have gathered existing resources and information about valproate and made it available on its website to help pharmacists to stay up-to-date.

The GPhC has also appealed to pharmacy teams to spread this important information in the sector.

New regulatory measures for valproate prescribing

The MHRA says:

From January 2024, valproate must not be started in new patients (male or female) younger than 55 years, unless two specialists independently consider and document that there is no other effective or tolerated treatment, or unless there are compelling reasons that the reproductive risks do not apply. For the majority of patients, other effective treatment options are available.

Women of childbearing potential and and girls who are currently taking valproate should be reviewed at their next annual specialist review, using a revised valproate Annual Risk Acknowledgement Form, which will include the need for a second opinion’s signature if the patient is to continue with valproate.

The regulatory measures will be introduced in a phased manner to ensure ongoing patient care is not disrupted, as recommended by the independent group Commission on Human Medicines

 

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue December 2023

Related articles

Sanofi Consumer Healthcare signs supply agreements with two wholesalers

Opella Healthcare, trading as Sanofi Consumer Healthcare, said it has entered into a dual partnership agreement with Alliance...

Sigma 2024 Conference: Rishi Sunak sends best wishes to all the participants

The 14th Annual Community Pharmacy Conference by Sigma Pharmaceuticals began on Monday, 25 February at Sun City, South...

Peak Pharmacy branches in Derbyshire and Staffordshire find new owners

‘There is a resurgence in demand for pharmacies that dispense below 4,000 items’ Independent pharmacy chain, Peak Pharmacy, has...

JAS UK granted WDA(H) license for its pharma and healthcare division

Securing the license empowers JAS UK's pharma and healthcare division to seamlessly connect with the company’s more than...